Cipla Ltd.

Cipla is eyeing to scale up its US core formulations sales on the back of respiratory and peptide franchises while monitoring upcoming complex product launches in the second half of the current fiscal. Besides, the company is betting big on digitisation and emerging segments like biosimilars and mRNA aided medications to drive its next phase of growth.

The drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply chain, HR, customer outreach and stakeholder engagement. Over the past few years, the company has set up several foundational elements to drive the digitisation and automation plans right from adopting latest trends to transform patient reach and customer care via digitalisation.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.